Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1996 Mar;70(3):2038–2043. doi: 10.1128/jvi.70.3.2038-2043.1996

In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects.

W J Lech 1, G Wang 1, Y L Yang 1, Y Chee 1, K Dorman 1, D McCrae 1, L C Lazzeroni 1, J W Erickson 1, J S Sinsheimer 1, A H Kaplan 1
PMCID: PMC190036  PMID: 8627733

Abstract

We have evaluated the sequence diversity of the protease human immunodeficiency virus type 1 in vivo. Our analysis of 246 protease coding domain sequences obtained from 12 subjects indicates that amino acid substitutions predicted to give rise to protease inhibitor resistance may be present in patients who have not received protease inhibitors. In addition, we demonstrated that amino acid residues directly involved in enzyme-substrate interactions may be varied in infected individuals. Several of these substitutions occurred in combination either more or less frequently than would be expected if their appearance was independent, suggesting that one substitution may compensate for the effects of another. Taken together, our analysis indicates that the human immunodeficiency virus type 1 protease has flexibility sufficient to vary critical subsites in vivo, thereby retaining enzyme function and viral pathogenicity.

Full Text

The Full Text of this article is available as a PDF (188.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cichutek K., Merget H., Norley S., Linde R., Kreuz W., Gahr M., Kurth R. Development of a quasispecies of human immunodeficiency virus type 1 in vivo. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7365–7369. doi: 10.1073/pnas.89.16.7365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Coffin J. M. Genetic diversity and evolution of retroviruses. Curr Top Microbiol Immunol. 1992;176:143–164. doi: 10.1007/978-3-642-77011-1_10. [DOI] [PubMed] [Google Scholar]
  3. Coffin J. M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995 Jan 27;267(5197):483–489. doi: 10.1126/science.7824947. [DOI] [PubMed] [Google Scholar]
  4. Collins J. R., Burt S. K., Erickson J. W. Flap opening in HIV-1 protease simulated by 'activated' molecular dynamics. Nat Struct Biol. 1995 Apr;2(4):334–338. doi: 10.1038/nsb0495-334. [DOI] [PubMed] [Google Scholar]
  5. Condra J. H., Schleif W. A., Blahy O. M., Gabryelski L. J., Graham D. J., Quintero J. C., Rhodes A., Robbins H. L., Roth E., Shivaprakash M. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995 Apr 6;374(6522):569–571. doi: 10.1038/374569a0. [DOI] [PubMed] [Google Scholar]
  6. Ferbas J., Kaplan A. H., Hausner M. A., Hultin L. E., Matud J. L., Liu Z., Panicali D. L., Nerng-Ho H., Detels R., Giorgi J. V. Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV CD8+ lymphocyte activity. J Infect Dis. 1995 Aug;172(2):329–339. doi: 10.1093/infdis/172.2.329. [DOI] [PubMed] [Google Scholar]
  7. Ho D. D., Neumann A. U., Perelson A. S., Chen W., Leonard J. M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995 Jan 12;373(6510):123–126. doi: 10.1038/373123a0. [DOI] [PubMed] [Google Scholar]
  8. Ho D. D., Toyoshima T., Mo H., Kempf D. J., Norbeck D., Chen C. M., Wideburg N. E., Burt S. K., Erickson J. W., Singh M. K. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J Virol. 1994 Mar;68(3):2016–2020. doi: 10.1128/jvi.68.3.2016-2020.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jacobsen H., Yasargil K., Winslow D. L., Craig J. C., Kröhn A., Duncan I. B., Mous J. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology. 1995 Jan 10;206(1):527–534. doi: 10.1016/s0042-6822(95)80069-7. [DOI] [PubMed] [Google Scholar]
  10. Kaplan A. H., Michael S. F., Wehbie R. S., Knigge M. F., Paul D. A., Everitt L., Kempf D. J., Norbeck D. W., Erickson J. W., Swanstrom R. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5597–5601. doi: 10.1073/pnas.91.12.5597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kaplan A. H., Zack J. A., Knigge M., Paul D. A., Kempf D. J., Norbeck D. W., Swanstrom R. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J Virol. 1993 Jul;67(7):4050–4055. doi: 10.1128/jvi.67.7.4050-4055.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kohl N. E., Emini E. A., Schleif W. A., Davis L. J., Heimbach J. C., Dixon R. A., Scolnick E. M., Sigal I. S. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4686–4690. doi: 10.1073/pnas.85.13.4686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kozal M. J., Shafer R. W., Winters M. A., Katzenstein D. A., Merigan T. C. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis. 1993 Mar;167(3):526–532. doi: 10.1093/infdis/167.3.526. [DOI] [PubMed] [Google Scholar]
  14. Kuiken C. L., Zwart G., Baan E., Coutinho R. A., van den Hoek J. A., Goudsmit J. Increasing antigenic and genetic diversity of the V3 variable domain of the human immunodeficiency virus envelope protein in the course of the AIDS epidemic. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9061–9065. doi: 10.1073/pnas.90.19.9061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kuroda M. J., el-Farrash M. A., Choudhury S., Harada S. Impaired infectivity of HIV-1 after a single point mutation in the POL gene to escape the effect of a protease inhibitor in vitro. Virology. 1995 Jun 20;210(1):212–216. doi: 10.1006/viro.1995.1334. [DOI] [PubMed] [Google Scholar]
  16. Larder B. A. 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 1992 Dec;36(12):2664–2669. doi: 10.1128/aac.36.12.2664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lin Y., Lin X., Hong L., Foundling S., Heinrikson R. L., Thaisrivongs S., Leelamanit W., Raterman D., Shah M., Dunn B. M. Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance. Biochemistry. 1995 Jan 31;34(4):1143–1152. doi: 10.1021/bi00004a007. [DOI] [PubMed] [Google Scholar]
  18. Loeb D. D., Swanstrom R., Everitt L., Manchester M., Stamper S. E., Hutchison C. A., 3rd Complete mutagenesis of the HIV-1 protease. Nature. 1989 Aug 3;340(6232):397–400. doi: 10.1038/340397a0. [DOI] [PubMed] [Google Scholar]
  19. Markham R. B., Yu X., Farzadegan H., Ray S. C., Vlahov D. Human immunodeficiency virus type 1 env and p17gag sequence variation in polymerase chain reaction-positive, seronegative injection drug users. J Infect Dis. 1995 Apr;171(4):797–804. doi: 10.1093/infdis/171.4.797. [DOI] [PubMed] [Google Scholar]
  20. Markowitz M., Mo H., Kempf D. J., Norbeck D. W., Bhat T. N., Erickson J. W., Ho D. D. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol. 1995 Feb;69(2):701–706. doi: 10.1128/jvi.69.2.701-706.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. McCutchan F. E., Hegerich P. A., Brennan T. P., Phanuphak P., Singharaj P., Jugsudee A., Berman P. W., Gray A. M., Fowler A. K., Burke D. S. Genetic variants of HIV-1 in Thailand. AIDS Res Hum Retroviruses. 1992 Nov;8(11):1887–1895. doi: 10.1089/aid.1992.8.1887. [DOI] [PubMed] [Google Scholar]
  22. McNearney T., Hornickova Z., Markham R., Birdwell A., Arens M., Saah A., Ratner L. Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10247–10251. doi: 10.1073/pnas.89.21.10247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Milich L., Margolin B., Swanstrom R. V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability. J Virol. 1993 Sep;67(9):5623–5634. doi: 10.1128/jvi.67.9.5623-5634.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Mohri H., Singh M. K., Ching W. T., Ho D. D. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):25–29. doi: 10.1073/pnas.90.1.25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Nájera I., Holguín A., Quiñones-Mateu M. E., Muñoz-Fernández M. A., Nájera R., López-Galíndez C., Domingo E. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol. 1995 Jan;69(1):23–31. doi: 10.1128/jvi.69.1.23-31.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Otto M. J., Garber S., Winslow D. L., Reid C. D., Aldrich P., Jadhav P. K., Patterson C. E., Hodge C. N., Cheng Y. S. In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7543–7547. doi: 10.1073/pnas.90.16.7543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Partaledis J. A., Yamaguchi K., Tisdale M., Blair E. E., Falcione C., Maschera B., Myers R. E., Pazhanisamy S., Futer O., Cullinan A. B. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol. 1995 Sep;69(9):5228–5235. doi: 10.1128/jvi.69.9.5228-5235.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Patick A. K., Rose R., Greytok J., Bechtold C. M., Hermsmeier M. A., Chen P. T., Barrish J. C., Zahler R., Colonno R. J., Lin P. F. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J Virol. 1995 Apr;69(4):2148–2152. doi: 10.1128/jvi.69.4.2148-2152.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Pedroza Martins L., Chenciner N., Wain-Hobson S. Complex intrapatient sequence variation in the V1 and V2 hypervariable regions of the HIV-1 gp 120 envelope sequence. Virology. 1992 Dec;191(2):837–845. doi: 10.1016/0042-6822(92)90259-r. [DOI] [PubMed] [Google Scholar]
  30. Peng C., Ho B. K., Chang T. W., Chang N. T. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J Virol. 1989 Jun;63(6):2550–2556. doi: 10.1128/jvi.63.6.2550-2556.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Phillips R. E., Rowland-Jones S., Nixon D. F., Gotch F. M., Edwards J. P., Ogunlesi A. O., Elvin J. G., Rothbard J. A., Bangham C. R., Rizza C. R. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature. 1991 Dec 12;354(6353):453–459. doi: 10.1038/354453a0. [DOI] [PubMed] [Google Scholar]
  32. Sardana V. V., Schlabach A. J., Graham P., Bush B. L., Condra J. H., Culberson J. C., Gotlib L., Graham D. J., Kohl N. E., LaFemina R. L. Human immunodeficiency virus type 1 protease inhibitors: evaluation of resistance engendered by amino acid substitutions in the enzyme's substrate binding site. Biochemistry. 1994 Mar 1;33(8):2004–2010. doi: 10.1021/bi00174a005. [DOI] [PubMed] [Google Scholar]
  33. Simmonds P., Zhang L. Q., McOmish F., Balfe P., Ludlam C. A., Brown A. J. Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis. J Virol. 1991 Nov;65(11):6266–6276. doi: 10.1128/jvi.65.11.6266-6276.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. St Clair M. H., Martin J. L., Tudor-Williams G., Bach M. C., Vavro C. L., King D. M., Kellam P., Kemp S. D., Larder B. A. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 1991 Sep 27;253(5027):1557–1559. doi: 10.1126/science.1716788. [DOI] [PubMed] [Google Scholar]
  35. Turriziani O., Antonelli G., Jacobsen H., Mous J., Riva E., Pistello M., Dianzani F. Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase. Acta Virol. 1994 Oct;38(5):297–298. [PubMed] [Google Scholar]
  36. Vartanian J. P., Meyerhans A., Henry M., Wain-Hobson S. High-resolution structure of an HIV-1 quasispecies: identification of novel coding sequences. AIDS. 1992 Oct;6(10):1095–1098. doi: 10.1097/00002030-199210000-00005. [DOI] [PubMed] [Google Scholar]
  37. Wei X., Ghosh S. K., Taylor M. E., Johnson V. A., Emini E. A., Deutsch P., Lifson J. D., Bonhoeffer S., Nowak M. A., Hahn B. H. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995 Jan 12;373(6510):117–122. doi: 10.1038/373117a0. [DOI] [PubMed] [Google Scholar]
  38. Winslow D. L., Stack S., King R., Scarnati H., Bincsik A., Otto M. J. Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors. AIDS Res Hum Retroviruses. 1995 Jan;11(1):107–113. doi: 10.1089/aid.1995.11.107. [DOI] [PubMed] [Google Scholar]
  39. Wlodawer A., Erickson J. W. Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem. 1993;62:543–585. doi: 10.1146/annurev.bi.62.070193.002551. [DOI] [PubMed] [Google Scholar]
  40. Zhang L. Q., MacKenzie P., Cleland A., Holmes E. C., Brown A. J., Simmonds P. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol. 1993 Jun;67(6):3345–3356. doi: 10.1128/jvi.67.6.3345-3356.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. di Marzo Veronese F., Reitz M. S., Jr, Gupta G., Robert-Guroff M., Boyer-Thompson C., Louie A., Gallo R. C., Lusso P. Loss of a neutralizing epitope by a spontaneous point mutation in the V3 loop of HIV-1 isolated from an infected laboratory worker. J Biol Chem. 1993 Dec 5;268(34):25894–25901. [PubMed] [Google Scholar]
  42. el-Farrash M. A., Kuroda M. J., Kitazaki T., Masuda T., Kato K., Hatanaka M., Harada S. Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor. J Virol. 1994 Jan;68(1):233–239. doi: 10.1128/jvi.68.1.233-239.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES